to discuss the performance of leronlimab in its cl
Post# of 148279
(Total Views: 516)
Posted On: 12/23/2022 10:00:20 AM
Re: generactor #131849
Quote:
to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.
Sounds pretty specific to me, "discuss the performance of leronlimab . . . and the recent charges . . ." I see nothing about this being the quarterly update, as described.
I assume they wrote this language to have meaning and the CC will be about the two things they state it will be about.
Why are you all (excluding generactor) suggesting it to be a quarterly when it does not say it is that?
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼